Tissue Regenix

What they do

Tissue Regenix Group manufactures and distributes regenerative medicine products built on two proprietary processing platforms: dCELL® and BioRinse™. The dCELL® technology is a decellularisation process — it strips donor tissue of cells while preserving the structural scaffold, allowing the recipient's own body to repopulate and regenerate the tissue naturally. BioRinse™ is a complementary platform focused on bone and soft tissue processing. Together, they address clinical needs across orthopaedics and related fields.

The company operates from two locations. The Leeds site houses the corporate offices and handles porcine tissue medical device manufacturing and distribution, including the OrthoPure® XT Ligament Reconstruction Implant. That facility is certified to ISO 13485:2016. It also serves as the research and development hub, with strong connections to the University of Leeds — where the dCELL® technology originated.

The San Antonio, Texas site — formerly known as CellRight Technologies — processes, stores and distributes Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P). It supplies hospitals, medical professionals and approved distribution partners across the United States and internationally, operating under FDA registration, AATB accreditation, and compliance with AATB Standards and relevant state regulations.

The products reach surgeons and clinicians who need tissue repair solutions that work with the body rather than against it. Regenerative medicine in this context means using processed donor tissue as a scaffold — the patient's own cells do the rebuilding. It is a different proposition from synthetic implants, and the clinical and health economic case rests on how well that natural regeneration proceeds.

Where they sit in Leeds

Leeds has a long-standing relationship with life sciences and medical technology, and Tissue Regenix is one of the more visible examples of University of Leeds research reaching commercial scale. The dCELL® platform was spun out from the university, and the Leeds site retains that R&D connection — meaning future portfolio development is likely to continue drawing on academic collaboration in the city.

The Leeds operation is the group's registered home and its manufacturing base for the porcine tissue side of the business. While the human tissue processing happens in Texas to meet FDA and AATB requirements, the scientific and corporate leadership sits in Yorkshire. That split reflects a practical reality in regenerative medicine: human tissue processing in the US is governed by a distinct regulatory framework that makes local processing necessary for that market.

For the Leeds tech and life sciences community, Tissue Regenix represents a relatively rare thing — a medtech company that has taken university IP through regulatory approval and into active clinical use across two continents. The OrthoPure® XT implant, manufactured in Leeds, is the clearest example of that journey from lab to operating theatre.

What they offer

• dCELL® platform — proprietary decellularisation technology that processes donor tissue into a natural scaffold for patient regeneration, applicable to soft tissue applications.
• BioRinse™ platform — complementary bone and soft tissue processing technology used in allograft preparation.
• OrthoPure® XT Ligament Reconstruction Implant — a porcine tissue medical device manufactured at the Leeds facility and distributed for ligament reconstruction procedures.
• HCT/P allografts (San Antonio) — human tissue products processed, stored and distributed from Texas to hospitals and medical professionals under FDA and AATB compliance.